On July 16, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported it has entered into a Memorandum of Understanding ("MoU"), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle’s proprietary microneedle technology for intradermal administration of BriaCell’s lead Phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The MoU reflects the continued commitment of BriaCell and Uneedle to collaborate on the potential regulatory and commercial development of BriaCell’s cell-based immunotherapy Bria-IMT. The non-binding MoU is intended to establish a plan that details scaling of Uneedle’s microneedle devices for use in commercial quantities. All activities and projections described herein are contingent upon successful regulatory approval of BriaCell’s lead Phase 3 clinical candidate, Bria-IMT, in the relevant jurisdictions.
Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). Uneedle’s microneedle technology is being used in this pivotal study to intradermally administer Bria-IMT.
"Efficient and reliable drug administration is integral to treating cancer patients," said William V. Williams, MD, President and Chief Executive Officer of BriaCell. "Uneedle’s microneedle technology is already being used in our pivotal Phase 3 study, and we believe this approach may support faster, more convenient administration and a more patient-friendly treatment experience."
"Precision and consistency in intradermal drug delivery are important attributes for therapies administered into the skin," said Jeroen Wissink, Chief Executive Officer of Uneedle. "We are excited to work with BriaCell to support the use of our proprietary microneedle technology for Bria-IMT and to help advance delivery readiness ahead of potential commercialization."
(Press release, BriaCell Therapeutics, JUL 16, 2026, View Source [SID1234669269])